Tapinarof Patent Expiration

Tapinarof is Used for managing plaque psoriasis in adults through topical application. It was first introduced by Organon Llc in its drug Vtama on May 23, 2022.


Tapinarof Patents

Given below is the list of patents protecting Tapinarof, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vtama US11497718 Use of tapinarof for the treatment of atopic dermatitis Nov 13, 2039 Organon Llc
Vtama US11590088 Use of Tapinarof for the treatment of chronic plaque psoriasis Nov 13, 2039 Organon Llc
Vtama US11938099 Use of tapinarof for the treatment of atopic dermatitis Nov 13, 2039 Organon Llc
Vtama US10647649 Process for preparing tapinarof Nov 13, 2038 Organon Llc
Vtama US11597692 Process for preparing tapinarof Nov 13, 2038 Organon Llc
Vtama US10195160 Topical pharmaceutical compositions May 19, 2036 Organon Llc
Vtama US10426743 Topical pharmaceutical compositions May 19, 2036 Organon Llc
Vtama US11458108 Topical pharmaceutical compositions May 19, 2036 Organon Llc
Vtama US11612573 Topical pharmaceutical compositions May 19, 2036 Organon Llc
Vtama US11617724 Topical pharmaceutical compositions May 19, 2036 Organon Llc
Vtama US11622945 Topical pharmaceutical compositions May 19, 2036 Organon Llc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tapinarof's patents.

Given below is the list recent legal activities going on the following patents of Tapinarof.

Activity Date Patent Number
Patent litigations
Review Certificate Mailed 17 Jul, 2025 US11590088
Notice of Final Determination -Eligible 27 Jun, 2025 US10195160
FDA Final Eligibility Letter 10 Jun, 2025 US10195160
Information Disclosure Statement (IDS) Filed 10 Jun, 2025 US10195160
Review Certificate 12 May, 2025 US11590088
Post Issue Communication - Dedicate Life of Patent to Public/Disclaimers 13 Mar, 2025 US11590088
Termination or Final Written Decision 07 Mar, 2025 US11590088
Request for Trial Granted 08 Nov, 2024 US11590088
Petition Requesting Trial 13 May, 2024 US11590088
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US10195160


Tapinarof's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Tapinarof Generic API Manufacturers

Given below is the list of companies who have filed for Tapinarof generic, along with the locations of their manufacturing plants worldwide.